Considering Predictive Oncology’s ongoing process to evaluate strategic alternatives, the Company has elected not to host an investor conference call this quarter. Predictive plans to host a corporate ...

Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive ...

Initial Bulk Sample Returns ... inclusion in this report of the matters based on the information in the form and context in ...

This study presents a valuable finding on the molecular mechanisms that govern GABAergic inhibitory synapse function. The authors propose that Endophilin A1 serves as a novel regulator of GABAergic ...

RKLB's strong revenue growth and market position in aerospace make it a promising investment opportunity with sustained ...

Three months later, we are pleased to report that hospitals representing about 2% of overall organ transplant volumes 3 have now signed up to use GraftAssure. We also received significant interest and ...

Screening: The micronized, purified material was then screened, via industry-standard sieve screening, to achieve the targeted particle sizes for subsequent spheronization (shaping); ...

Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...

Welcome, ladies and gentlemen, to the third quarter of fiscal year 2024 earnings conference call for Organogenesis Holdings, ...

Lucid Diagnostics Inc.  ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: ...